Harbour Investments’s Pacira BioSciences PCRX Stock Holding History

Harbour Investments’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100	Closed	-$2.58K	–	3980
2025 Q3	$2.58K	Hold	100	–	–	﹤0.01%	3209
2025 Q2	$2.39K	Buy	+100	New	+$2.52K	﹤0.01%	3086
2024 Q4	–	Sell	-50	Closed	-$753	–	3566
2024 Q3	$753	Buy	50 +20	+67%	+$342	﹤0.01%	3140
2024 Q2	$858	Sell	30 -65	-68%	-$1.85K	﹤0.01%	3017
2024 Q1	$2.78K	Buy	+95	New	+$2.92K	﹤0.01%	2684
2023 Q3	–	Sell	-13	Closed	-$521	–	3075
2023 Q2	$521	Hold	13	–	–	﹤0.01%	2811
2023 Q1	$531	Buy	+13	New	+$517	﹤0.01%	2801
2021 Q4	–	Sell	-695	Closed	-$39K	–	3397
2021 Q3	$39K	Buy	695 +1	+0.1%	+$58	﹤0.01%	1927
2021 Q2	$42K	Hold	694	–	–	﹤0.01%	1923
2021 Q1	$49K	Buy	+694	New	+$49.6K	﹤0.01%	1715

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Harbour Investments's PCRX Position: Q4 2025 in Review

Harbour Investments sold out of Pacira BioSciences (PCRX) in Q4 2025, closing a stake of 100 shares — an estimated $2.58K sold.

Harbour Investments first reported a position in PCRX in Q1 2021 and held it in 10 quarters. The position peaked at $49K in Q1 2021. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2025.

Harbour Investments reported no remaining Pacira BioSciences position as of Q4 2025 after selling out during the quarter.
Harbour Investments sold 100 Pacira BioSciences shares in Q4 2025, an estimated $2.58K.
Harbour Investments first reported a position in Pacira BioSciences in Q1 2021 and held it in 10 quarters.
Harbour Investments's Pacira BioSciences position peaked at $49K in Q1 2021.
260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2025.

Based on Harbour Investments's 13F filing for Q4 2025, filed 9 Feb 2026.